Group items tagged

The Company Chemists' Association (CCA) has called for an evidence-based approach to hub and spoke dispensing proposals, stating that it is vital to back the changes based on robust data and lived experience of pharmacy businesses. Community pharmacy contractors need to to respond to a Department of Health and Social Care initiated consultation on the hub-and-spoke dispensing models by June 8. Malcolm Harrison, CEO of the CCA, said: "I am very concerned by both the number and scale of the assumptions contained within the impact assessment, which are unlikely to come to fruition. "The impact Assessment also makes predictions on a yet un-born market, stretching 10 years into the future. Hub and spoke technologies do have the potential to enable new dispensing models in the future if new commissioning can support a change in operations. I would caution against firm predictions about likely benefits without stronger commitments to enablers of change."

The Centre for Pharmacy Post-Graduate Education (CPPE) has launched Menopause - an introduction for pharmacy professionals e-learning programme. The new Menopause: an introduction for pharmacy professionals e-learning programme aims to support pharmacist's to increase their knowledge and awareness of menopause and perimenopause, helping them to have initial conversations with those who need support. The programme teaches how to equip people experiencing menopausal symptoms with evidence-based information that allows them to make decisions about their own health management. This e-learning programme considers a range of topics, including the signs and symptoms associated with menopause and perimenopause, how a diagnosis is made and the national context supporting a growing role for pharmacy professionals in menopause care. It also discusses the benefits and risks of treatment options available, the common misconceptions that people may have about menopause and how to apply the evidence base to practice in order to help support decision making.

Family Medicine and Internal Medicine: An Evidence-Based Approach is organized by American Medical Seminars (AMS), Inc. from Mar 06 - 09, 2023 in Sarasota, Florida, USA

The UK based Pharma giant Futura Medical Plc's lead product, Eroxon, a topical Stim-gel is now available on NHS prescription in England and Wales for the treatment of Erectile Dysfunction (ED). The Muti-Drug Resistant (MDR) approved alternative to PDE5i, Eroxon is available as an over-the counter off shelf at retailers like Boots and Superdrug; and is available on NHS prescription in England and Wales as a CE-marked medical device. Erectile dysfunction (ED), also known as impotence, is the inability to get and maintain an erection, typically concerning men over the age of 40 due to both, psychological and physical causes such as anxiety, depression, diabetes, and obesity. According to UK Conformity Assessed (UKCA), the approval of the medication is based on evidence from 2 Phase three clinical studies, which showed that 60 per cent of patients taking Eroxon achieved Minimal Clinically Important Differences (MCID) at 12 weeks.

joint pains are the commonly available supplements, glucosamine, chondroitin, or a combination of the two appear to have the greatest efficacy based on clinical trials, but a number of researchers remain guarded even when recommending those products. MSM may provide some benefits, but more studies need to be done before evidence accrues as to its long-term effectiveness.

To help transform care for patients, the Royal Pharmaceutical Society (RPS) is calling on the General Pharmaceutical Council (GPhC) to remove the two-year post qualification wait for pharmacists before they are allowed to start their independent prescriber training. RPS proposes that entry to training should be based on whether pharmacists can evidence the necessary skills, knowledge, and experience to undertake the training, and not the length of time a pharmacist has been on the register. RPS president Claire Anderson said: "We've campaigned strongly for better use of pharmacist independent prescribers, who are becoming essential to multi professional teams in all health care settings. "We want to ensure pharmacy remains an attractive career and has parity with the other professions. Pharmacist prescribing is now moving from being a skill only associated with advanced specialist levels of practice to a more generalist scope, providing a workforce that's more flexible with a shared set of capabilities.

A three-year contract has been signed between NHS Education for Scotland (NES) and Pharmaceutical Press, the Royal Pharmaceutical Society's (RPS) knowledge business, to continue the supply of trusted medicines information though MedicinesComplete, to healthcare professionals in Scotland. The renewed investment from NES demonstrates unequivocal confidence in the publisher and highlights Pharmaceutical Press' ongoing commitment to provide practical and evidence-based guidance, supporting those who prescribe, dispense, and administer medicines. Essential resources include Martindale: The Complete Drug Reference, Palliative Care formulary, Stockley's Drug Interactions and Critical Illness. Relied on by healthcare professionals globally for use in everyday practice, clear and concise guidance through MedicinesComplete supports confident decision-making at the point of care.

PAINWeek 2023 remains the US pain conference with the most expansive curriculum and is the favorite destination for frontline practitioners to enhance their competence in pain management. 75+ hours of the most up-to-date evidence-based scientific instruction available * Cutting-edge educational sessions * Faculty who are leaders in their field

The Health Select Committee Expert Panel has concluded in its report published on Tuesday (25 July) that the funding aspect in the community pharmacy sector 'requires improvement' based on the evidence received. The Expert Panel reviewed nine Government commitments, seven of which were from the Community Pharmacy Contractual Framework. It was found that available funding was not sufficient to keep pharmacies open, struggling financially with increased demand for dispensing, workforce pressures and rising costs due to inflation. One of the other commitments requiring improvement covered a scheme intended to protect access to local physical NHS pharmaceutical services in areas where there were fewer pharmacies. Professor Dame Jane Dacre, Chair of the Expert Panel, said: "Pharmacy plays a key role in the delivery of care so it's disappointing that progress overall to deliver on the Government's commitments was rated as 'requires improvement'.

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.

There is clear evidence that the majority of distance selling pharmacies are operating in breach of their NHS contracts, and a failure to properly regulate 'pseudo' distance selling pharmacies is leading to local pharmacy closures, the Company Chemists' Association has reported. According to the CCA's recent findings, 72 per cent of DSPs dispense over 50 per cent of their prescriptions to patients within a single postcode area within 10 miles of the pharmacy. "Operating within constrained geographical regions, pseudo-DSPs achieve reduced overheads and operational costs by focusing on localised marketing and medicine delivery. They compete against local brick-and-mortar pharmacies, causing them to lose vital trade," the CCA claimed, based on its recent survey - The Impact of Pseudo Distance Selling Pharmacies. "As per their terms of service, DSPs are obligated to provide prescription delivery nationwide, extending beyond local patients," said the CCA, adding that the financial savings resulting from the lack of patient access are balanced by the necessity to function on a national scale.

Hospital Procedures Consultants (HPC) provides quality, and evidence-based procedural education to emergency and hospitalist healthcare providers

The Royal Pharmaceutical Society (RPS) and the National Institute for Health Research (NIHR), supported by the Association of Pharmacy Technicians UK (APTUK), have launched the first e-learning module in a series for pharmacists and pharmacy technicians to develop their skills and knowledge in research. A total of nine e-learning modules will be released by the end of 2022 to improve research awareness, knowledge and skills for pharmacists and pharmacy technicians with little or no experience of research or research opportunities. The aim is to improve the capacity of pharmacy professionals to provide the evidence base to improve the practice of pharmacy and the health of the public. RPS President Professor Claire Anderson said: "Many pharmacy professionals are rather daunted by getting involved in research. Indeed, we have heard from pharmacists undertaking our post-registration credentialing assessments that the Research domain can present a real challenge.

The All-Party Parliamentary Group (APPG) on Pharmacy published a new report on Monday (January 23) that calls for "urgent action" to relieve funding pressure so there are "opportunities" for community pharmacy teams to deliver even more for their patients. The report highlights the need for a new "strategic vision" for pharmacy and highlights opportunities for the network to be empowered to deliver even more for patients. However, the manifesto also underlines that there are the very real risks that this opportunity may be lost if significant and ongoing pressures are not addressed. The recommendations are based on written and oral evidence gathered from frontline pharmacists, GPs, professional bodies and healthcare experts. To harness the potential of pharmacy, the report recommends the Government must take urgent action to relieve the funding pressures on the community pharmacy sector in the short term and review the long-term funding model for pharmacy. It also suggested the Government must harness the power of pharmacy to help the NHS deal with the COVID-19 backlog and the UK's growing healthcare challenges. It further recommended that future commissioning and funding must recognise that community pharmacy is the front door to the NHS for many patients.

The Hospitalist and Emergency Procedures is an Online CME curriculum that will provide current, evidence-based information about the common bedside procedures performed in the emergency room, intensive care unit, and hospital wards

Employ evidence-based strategies to integrate emerging immune checkpoint inhibitors and adoptive T-cell therapies into current clinical paradigms for advanced/metastatic melanoma

Health authorities in India have launched an inquiry into an allegation that a local pharmaceutical regulator, in return for a bribe, helped switch samples of cough syrups that the World Health Organization (WHO) had linked to the deaths of children in Gambia before the samples were tested at an Indian laboratory, according to two government officials and documents reviewed by the Reuters news agency. In an April 29 letter to the Anti-Corruption Bureau (ACB) in Haryana state reviewed by the news agency, a lawyer named Yashpal accused the state's drug controller, Manmohan Taneja, of taking a bribe of 50 million rupees (£481,600 approx.) from local manufacturer Maiden Pharmaceuticals to help it switch the samples before an Indian government laboratory tested them. Maiden's factory is based in Haryana state. Reuters points out that it was unable to independently establish that any bribes were paid. Taneja did not respond to phone calls, messages or emails seeking comment. Maiden did not respond to requests for comment. The WHO said it had no knowledge of the allegation. Yashpal - who like some Indians uses only one name - did not say in the letter where he got the information, or provide evidence for his claim about the syrups made by Maiden. Reuters was unable to independently establish that any bribes were paid.

An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Lilly's drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer's by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer's proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death. The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB). Using that scale, experts said Lilly's findings were roughly on par with Eisai Co Ltd and Biogen Inc's lecanemab, sold under the brand name Leqembi, which reduced cognitive decline by 27% in patients with early Alzheimer's in a study published last year. The results drove Lilly's shares to a record high, up more than 6% at $429.85. Dr. Ronald Petersen, an Alzheimer's researcher at Mayo Clinic, said Lilly's trial is the third to show removing amyloid from the brain slows progression of the disease, which could put to rest some lingering doubts about the benefits of drugs in the class and the amyloid-lowering theory. "It's modest, but I think it's real," he said of the benefit, "and I think it's clinically meaningful." Dr. Erik Musiek, a Washington University neurologist at Barnes-Jewish Hospital, said the efficacy looks as good or better than lecanemab.

The 14th Annual Emirates Cardiac Society Conference 2023 is organized by Lumina Organizers and ECS and will be held from Nov 24 - 26, in Dubai, UAE.This conference is designed to deliver an engaging forum to critically examine evidence-based strategies as well as contemporary best practices and clinical decision-making to reach our common objective of improving the heart health of patients with cardiovascular disease.